Preventive, corrective, and therapeutic agents for dry eye
Apocynin-based ophthalmic preparations stabilize the tear film and treat corneal epithelial damage and meibomian gland dysfunction, effectively addressing the multifaceted challenges of dry eye with improved efficacy and safety over existing treatments.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- TSUBOTA LAB
- Filing Date
- 2026-04-01
- Publication Date
- 2026-07-07
AI Technical Summary
Current treatments for dry eye, particularly those targeting tear film instability and meibomian gland dysfunction, are inadequate in providing comprehensive relief and often come with side effects, while apocynin's effects on these conditions are unknown.
Apocynin is formulated into ophthalmic preparations, such as eye drops or ointments, to stabilize the tear film, treat corneal epithelial damage, and address meibomian gland dysfunction, offering a multifaceted approach to dry eye prevention and treatment.
Apocynin effectively stabilizes the tear film, treats corneal epithelial damage, and addresses meibomian gland dysfunction, providing significant preventive and therapeutic benefits for various types of dry eye, including evaporative and tear-deficient forms, with minimal side effects.
Smart Images
Figure 2026113573000002 
Figure 2026113573000003 
Figure 2026113573000004